Disease Info Card

Late Adverse Effect

Information about Late Adverse Effect: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Late Adverse Effect

Most recent studies have shown that Late Adverse Effect shares some biological mechanisms with acute-lymphocytic-leukemia, brain-neoplasms, carcinoma, depressive-disorder, fibrosis, hodgkin-disease, illusions, leukemia, lymphoma, malignant-childhood-neoplasm, malignant-neoplasms, malignant-paraganglionic-neoplasm, neoplasms, neoplasms-radiation-induced, neoplasms-second-primary, nervousness, pain, radiation-injury, sarcoma, sequelae-aspects.

Among the many pathways, these few ones have gauged particular interests from scientists studying Late Adverse Effect, and have been seen in publications frequently: Aging, Cell Death, Cognition, Enucleation, Excretion, Insulin Secretion, Lactation, Lateral Inhibition, Localization, Locomotion, Parturition, Pathogenesis, Proprioception, Reflex, Regeneration, Secretion, Sensory Processing, Translation, Transport, Visual Perception

Quite a number of genes have been found to play important roles in Late Adverse Effect, such as CALCR, CALR, CAT, CRAT, CTBP1, GLYAT, IGKV1-5, INS, MAPT, MCAT, MID1, MMP12, NOL3, POMT1, SLC25A5, SLC6A8, TNF, TNFSF14. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.